DiFusion recently completed a series of in vivo and in vitro clinical tests. These tests were performed by third party institutions whereby the results showed CleanFUZE™ eradicated 99.998% of ...
Five-member board brings hands-on leadership in biomaterials commercialization, medical technology, spine innovation, OEM ...
AUSTIN, Texas, Oct. 7 /PRNewswire/ -- DiFUSION Technologies is a medical device company focused on the development and commercialization of its proprietary CleanFUZE™ antimicrobial technology for ...
AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE) -- DiFusion Therapeutic Biomaterials today announced that it will use the ...
AUSTIN, Texas, Jan. 14, 2025 /PRNewswire/ -- DiFusion Technologies, an industry leader in advanced biomaterials for surgical implants, announced today the issuance of a new US Patent 12,178,936 B2 ...
AUSTIN, Texas--(BUSINESS WIRE)--DiFusion Technologies, Inc. today announced promising data for the company’s ZFUZE Immuno-Stealth™ Surgical Polymer. The data and the importance of the immune system ...
AUSTIN, Texas--(BUSINESS WIRE)--DiFusion Technologies, maker of the ZFUZE™ suite of surgical polymers, today announced the addition of Todd Potokar to its Board of Directors. In addition, Rich Grant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results